UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Clinical pharmacology and therapeutics, 2012-02, Vol.91 (2), p.321-326

2012

Volltextzugriff (PDF)

Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.164-172

2009

Volltextzugriff (PDF)

Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait

Clinical pharmacology and therapeutics, 2017-03, Vol.101 (3), p.373-381

2017

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Clinical pharmacology and therapeutics, 2014-04, Vol.95 (4), p.376-382

2014

Volltextzugriff (PDF)

Pharmacogenomics and Individualized Medicine: Translating Science Into Practice

Clinical pharmacology and therapeutics, 2012-10, Vol.92 (4), p.467-475

2012

Volltextzugriff (PDF)

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease

Pediatrics (Evanston), 2016-07, Vol.138 (1)

2016

Volltextzugriff (PDF)

Development and use of active clinical decision support for preemptive pharmacogenomics

Journal of the American Medical Informatics Association : JAMIA, 2014-02, Vol.21 (e1), p.e93-e99

2014

Volltextzugriff (PDF)

An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia

Clinical pharmacology and therapeutics, 2017-03, Vol.101 (3), p.391-395

2017

Volltextzugriff (PDF)

Comparison of genome sequencing and clinical genotyping for pharmacogenes

Clinical pharmacology and therapeutics, 2016-10, Vol.100 (4), p.380-388

2016

Volltextzugriff (PDF)

The Case for Pharmacogenetics‐Guided Prescribing of Codeine in Children

Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1300-1302

2019

Volltextzugriff (PDF)

Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

Clinical chemistry (Baltimore, Md.), 2015-05, Vol.61 (5), p.775-776

2015

Volltextzugriff (PDF)

Cancer Pharmacogenomics

Clinical pharmacology and therapeutics, 2011-09, Vol.90 (3), p.461-466

2011

Volltextzugriff (PDF)

Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods

Clinical pharmacology and therapeutics, 2012-09, Vol.92 (3), p.360-365

2012

Volltextzugriff (PDF)

High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma

Cancer, 2004-04, Vol.100 (8), p.1724-1733

2004

Volltextzugriff (PDF)

Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors

Clinical cancer research, 2004-02, Vol.10 (3), p.840-848

2004

Volltextzugriff (PDF)

Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors

Journal of clinical oncology, 2006-02, Vol.24 (4), p.563-570

2006

Volltextzugriff (PDF)

Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia

Cancer, 2010-01, Vol.116 (1), p.227-232

2010

Volltextzugriff (PDF)

Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases

Journal of clinical oncology, 2001-06, Vol.19 (11), p.2804-2811

2001

Volltextzugriff (PDF)

Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia

Journal of clinical oncology, 2002-10, Vol.20 (20), p.4217-4224

2002

Volltextzugriff (PDF)

Individualizing chemotherapeutic treatment of colorectal cancer

American journal of health-system pharmacy, 2006-05, Vol.63 (9 Supplement 2), p.S12-S17

Crews, Kristine R

2006

Volltextzugriff (PDF)

Altered Irinotecan Pharmacokinetics in Pediatric High-Grade Glioma Patients Receiving Enzyme-inducing Anticonvulsant Therapy

Clinical cancer research, 2002-07, Vol.8 (7), p.2202-2209

2002

Volltextzugriff (PDF)

High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003-05, Vol.788 (1), p.65-74

2003

Volltextzugriff (PDF)

Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors

Cancer chemotherapy and pharmacology, 2006, Vol.57 (1), p.15-24

2006

Volltextzugriff (PDF)

Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high‐grade gliomas and receive enzyme‐inducing anticonvulsant therapy

Cancer, 2003-05, Vol.97 (S9), p.2374-2380

2003

Volltextzugriff (PDF)

Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma

Journal of pediatric hematology/oncology, 2004-11, Vol.26 (11), p.764-767

2004

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(38)
Humans
(36)
Biological And Medical Sciences
(21)
Male
(21)
Medical Sciences
(19)
Female
(18)
Pharmacology & Pharmacy
(16)
Child
(15)
Adolescent
(14)
Pharmacology. Drug Treatments
(13)
Child, Preschool
(11)
Oncology
(11)
Adult
(10)
Antineoplastic Agents
(9)
Camptothecin - Analogs & Derivatives
(8)
Animals
(7)
Camptothecin - Pharmacokinetics
(6)
Infant
(6)
Chemotherapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia

Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Pharmacogenomics and Individualized Medicine: Translating Science Into Practice

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease

Development and use of active clinical decision support for preemptive pharmacogenomics

An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia

Comparison of genome sequencing and clinical genotyping for pharmacogenes

The Case for Pharmacogenetics‐Guided Prescribing of Codeine in Children

Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

Cancer Pharmacogenomics

Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods

High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma

Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors

Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors

Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia

Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases

Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia

Individualizing chemotherapeutic treatment of colorectal cancer

Altered Irinotecan Pharmacokinetics in Pediatric High-Grade Glioma Patients Receiving Enzyme-inducing Anticonvulsant Therapy

High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma

Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors

Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high‐grade gliomas and receive enzyme‐inducing anticonvulsant therapy

Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma

Suchergebnisse filtern